{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:16:21Z","timestamp":1791105381130,"version":"4.1.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2011,9,26]],"date-time":"2011-09-26T00:00:00Z","timestamp":1316995200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,10]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>Mycophenolate mofetil (MMF) is now commonly used in pediatric liver transplant recipients, but no clear recommendations about the dosing regimen have been made for this population. The aim of this study was to determine the MMF dosage required for pediatric liver transplant recipients to achieve an area under the plasma concentration\u2013time curve from 0 to 12 hours (AUC<jats:sub>0-12<\/jats:sub>) for mycophenolic acid (MPA) greater than 30 mg hour\/L. A pharmacokinetic study of 15 children (median age = 8.3 years, range = 1.1-15.2 years) was performed at a median of 11.0 months (range = 0.5-88.0 months) after liver transplantation. MMF was initially introduced at a median starting dose of 300 mg\/m<jats:sup>2<\/jats:sup> twice a day (range = 186-554 mg\/m<jats:sup>2<\/jats:sup> twice a day). Thirteen of the 15 patients had an MPA AUC<jats:sub>0-12<\/jats:sub> value less than 30 mg hour\/L. The MMF dosage had to be increased in all patients except 1. The MMF dosage required to reach an MPA AUC<jats:sub>0-12<\/jats:sub> value greater than the defined target of 30 mg hour\/L ranged from 371 to 1014 mg\/m<jats:sup>2<\/jats:sup>\/day. For 2 patients who received rifampin in addition to MMF, the MPA AUC<jats:sub>0-12<\/jats:sub> value remained low despite a 2-fold increase in the MMF dosage. In conclusion, an initial MMF dose of 600 mg\/m<jats:sup>2<\/jats:sup> twice a day led to MPA AUC<jats:sub>0-12<\/jats:sub> values greater than the 30 mg hour\/L threshold except when rifampin was coadministered. Because of the important interindividual variability of MPA pharmacokinetics, therapeutic drug monitoring is recommended for optimizing the daily MMF dosage. Furthermore, these results suggest that the coadministration of MPA with rifampin should be avoided. Liver Transpl 17:1152\u20131158, 2011. \u00a9 2011 AASLD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/lt.22364","type":"journal-article","created":{"date-parts":[[2011,6,21]],"date-time":"2011-06-21T15:05:05Z","timestamp":1308668705000},"page":"1152-1158","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":18,"title":["Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients"],"prefix":"10.1097","volume":"17","author":[{"given":"Caroline","family":"Barau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Barrail-Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Hemerziu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalila","family":"Habes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Taburet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Debray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Furlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"suppl","key":"R1-5-20250124","first-page":"S181S190","article-title":"Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection.","volume":"80","author":"Allison","year":"2005","journal-title":"Transplantation"},{"issue":"suppl","key":"R2-5-20250124","first-page":"S142S146","article-title":"Indications of mycophenolate mofetil in liver transplantation.","volume":"80","author":"Klupp","year":"2005","journal-title":"Transplantation"},{"key":"R3-5-20250124","doi-asserted-by":"crossref","first-page":"442450","DOI":"10.1053\/jlts.2001.23356","article-title":"A randomized doubleblind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients.","volume":"7","author":"Wiesner","year":"2001","journal-title":"Liver Transpl"},{"key":"R4-5-20250124","doi-asserted-by":"crossref","first-page":"224229","DOI":"10.1097\/00007890-200101270-00009","article-title":"Use of mycophenolate mofetil as rescue therapy after pediatric liver transplantation.","volume":"71","author":"Chardot","year":"2001","journal-title":"Transplantation"},{"key":"R5-5-20250124","doi-asserted-by":"crossref","first-page":"15751580","DOI":"10.1097\/01.TP.0000163504.29054.3F","article-title":"Mycophenolate mofetil for renal dysfunction after pediatric liver transplantation.","volume":"79","author":"Evans","year":"2005","journal-title":"Transplantation"},{"key":"R6-5-20250124","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.2165\/00003088-200746010-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.","volume":"46","author":"Staatz","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"R7-5-20250124","doi-asserted-by":"crossref","first-page":"119128","DOI":"10.1097\/00007691-200104000-00005","article-title":"Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid.","volume":"23","author":"van Gelder","year":"2001","journal-title":"Ther Drug Monit"},{"key":"R8-5-20250124","doi-asserted-by":"crossref","first-page":"759768","DOI":"10.1681\/ASN.V133759","article-title":"The pharmacokineticpharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy.","volume":"13","author":"Weber","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R9-5-20250124","doi-asserted-by":"crossref","first-page":"978984","DOI":"10.1007\/s004670100006","article-title":"The use of mycophenolate mofetil suspension in pediatric renal allograft recipients.","volume":"16","author":"Bunchman","year":"2001","journal-title":"Pediatr Nephrol"},{"key":"R10-5-20250124","doi-asserted-by":"crossref","first-page":"609622","DOI":"10.1097\/00007691-200310000-00011","article-title":"Twelvemonth evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil.","volume":"25","author":"Kuypers","year":"2003","journal-title":"Ther Drug Monit"},{"key":"R11-5-20250124","doi-asserted-by":"crossref","first-page":"429455","DOI":"10.2165\/00003088-199834060-00002","article-title":"Clinical pharmacokinetics of mycophenolate mofetil.","volume":"34","author":"Bullingham","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"R12-5-20250124","doi-asserted-by":"crossref","first-page":"15111520","DOI":"10.1681\/ASN.V981511","article-title":"Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients.","volume":"9","author":"Weber","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"R13-5-20250124","doi-asserted-by":"crossref","first-page":"268276","DOI":"10.1177\/00912700122010087","article-title":"Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus.","volume":"41","author":"Jain","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"R14-5-20250124","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1177\/0091270004270145","article-title":"Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients.","volume":"45","author":"Pisupati","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"R15-5-20250124","doi-asserted-by":"crossref","first-page":"791796","DOI":"10.1002\/lt.21146","article-title":"Pharmacokinetics of mycophenolic acid in liver transplant patients after intravenous and oral administration of mycophenolate mofetil.","volume":"13","author":"Jain","year":"2007","journal-title":"Liver Transpl"},{"key":"R16-5-20250124","doi-asserted-by":"crossref","first-page":"541546","DOI":"10.1097\/01.tp.0000200307.79962.48","article-title":"Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil.","volume":"81","author":"Brunet","year":"2006","journal-title":"Transplantation"},{"key":"R17-5-20250124","first-page":"442447","article-title":"Use of rifampin for severe pruritus in children with chronic cholestasis.","volume":"29","author":"Yerushalmi","year":"1999","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R19-5-20250124","doi-asserted-by":"crossref","first-page":"100104","DOI":"10.1007\/s004670050021","article-title":"Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression.","volume":"14","author":"Filler","year":"2000","journal-title":"Pediatr Nephrol"},{"key":"R20-5-20250124","doi-asserted-by":"crossref","first-page":"383388","DOI":"10.1053\/jlts.2003.50022","article-title":"Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients.","volume":"9","author":"Aw","year":"2003","journal-title":"Liver Transpl"},{"key":"R21-5-20250124","doi-asserted-by":"crossref","first-page":"987994","DOI":"10.1046\/j.1600-6143.2005.00779.x","article-title":"Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistanceassociated protein 2.","volume":"5","author":"Hesselink","year":"2005","journal-title":"Am J Transplant"},{"key":"R22-5-20250124","doi-asserted-by":"crossref","first-page":"15701575","DOI":"10.1002\/lt.21274","article-title":"Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine.","volume":"13","author":"Lobritto","year":"2007","journal-title":"Liver Transpl"},{"key":"R23-5-20250124","doi-asserted-by":"crossref","first-page":"727733","DOI":"10.1097\/FTD.0b013e3181c01d07","article-title":"Agerelated variability of mycophenolate mofetil exposure in stable pediatric liver transplant recipients and influences of donor characteristics.","volume":"31","author":"Parant","year":"2009","journal-title":"Ther Drug Monit"},{"key":"R24-5-20250124","first-page":"609619","article-title":"Comparison of liquid chromatographytandem mass spectrometry with a commercial enzymemultiplied immunoassay for the determination of plasma MPA in renal transplant recipients and consequences for therapeutic drug monitoring.","volume":"26","author":"Premaud","year":"2004","journal-title":"Ther Drug Monit"},{"key":"R25-5-20250124","doi-asserted-by":"crossref","first-page":"11851187","DOI":"10.1016\/S0041-1345(98)00201-2","article-title":"Therapeutic drug monitoring of mycophenolic acid: comparison of HPLC and immunoassay reveals new MPA metabolites.","volume":"30","author":"Schutz","year":"1998","journal-title":"Transplant Proc"},{"key":"R26-5-20250124","doi-asserted-by":"crossref","first-page":"492500","DOI":"10.1016\/S0009-9236(99)70012-3","article-title":"The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients.","volume":"66","author":"Johnson","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"R27-5-20250124","doi-asserted-by":"crossref","first-page":"23872401","DOI":"10.1016\/j.clinthera.2008.12.017","article-title":"Models for the prediction of mycophenolic acid area under the curve using a limitedsampling strategy and an enzyme multiplied immunoassay technique in Chinese patients undergoing liver transplantation.","volume":"30","author":"Chen","year":"2008","journal-title":"Clin Ther"},{"key":"R28-5-20250124","doi-asserted-by":"crossref","first-page":"428432","DOI":"10.1097\/00007890-199202010-00031","article-title":"RS61443a phase I clinical trial and pilot rescue study.","volume":"53","author":"Sollinger","year":"1992","journal-title":"Transplantation"},{"key":"R29-5-20250124","doi-asserted-by":"crossref","first-page":"351361","DOI":"10.1016\/j.clpt.2005.06.007","article-title":"The impact of uridine diphosphateglucuronosyltransferase 1A9 (UGT1A9) gene promoter region singlenucleotide polymorphisms T275A and C2152T on early mycophenolic acid doseinterval exposure in de novo renal allograft recipients.","volume":"78","author":"Kuypers","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"R30-5-20250124","doi-asserted-by":"crossref","first-page":"819850","DOI":"10.2165\/00003088-200342090-00003","article-title":"Pharmacokinetic interactions with rifampicin: clinical relevance.","volume":"42","author":"Niemi","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"R31-5-20250124","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1345\/aph.19069","article-title":"Renal allograft dysfunction associated with rifampintacrolimus interaction.","volume":"34","author":"Chenhsu","year":"2000","journal-title":"Ann Pharmacother"},{"key":"R32-5-20250124","doi-asserted-by":"crossref","first-page":"9196","DOI":"10.1177\/00912709922007499","article-title":"Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers.","volume":"39","author":"Hebert","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"R33-5-20250124","doi-asserted-by":"crossref","first-page":"509521","DOI":"10.1016\/j.clpt.2006.08.002","article-title":"Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients.","volume":"80","author":"Naesens","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"R34-5-20250124","doi-asserted-by":"crossref","first-page":"8893","DOI":"10.1016\/j.transproceed.2006.10.189","article-title":"Noninfectious gastrointestinal (GI) complications of mycophenolic acid therapy: a consequence of local GI toxicity?","volume":"39","author":"Arns","year":"2007","journal-title":"Transplant Proc"},{"key":"R35-5-20250124","doi-asserted-by":"crossref","first-page":"261266","DOI":"10.1097\/00007890-199907270-00018","article-title":"A randomized doubleblind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.","volume":"68","author":"van Gelder","year":"1999","journal-title":"Transplantation"},{"key":"R36-5-20250124","doi-asserted-by":"crossref","first-page":"7889","DOI":"10.1016\/j.trre.2011.01.001","article-title":"Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation.","volume":"25","author":"Tonshoff","year":"2011","journal-title":"Transplant Rev (Orlando)"}],"container-title":["Liver Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.22364","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.22364","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01445473-201110000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T17:08:34Z","timestamp":1737738514000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01445473-201110000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1002\/lt.22364","relation":{},"ISSN":["1527-6465"],"issn-type":[{"value":"1527-6465","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}